The inhibitory effect of the proinflammatory cytokine TNFα on erythroid differentiation involves erythroid transcription factor modulation

International Journal of Oncology

Volumn 34, Issue 3, 2009, Pages 853-860

  Buck, Isabelle ^a   Morceau, Franck ^a   Cristofanon, Silvia ^a   Reuter, Simone ^a   Dicato, Mario ^a   Diederich, Marc ^a  

^a LABORATOIRE DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE DU CANCER   (Luxembourg)

Author keywords

Anemia; Cancer; Friend of GATA 1; GATA 1 2; Inflammation; Tumor necrosis factor

Indexed keywords

ACLACINOMYCIN; CYTOKINE; DOXORUBICIN; ERYTHROPOIETIN RECEPTOR; GAMMA GLOBIN; GLYCOPHORIN A; HEMIN; PROTEASOME; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR GATA 2; TUMOR NECROSIS FACTOR ALPHA;

ACETYLATION; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELL LINEAGE; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG MECHANISM; ERYTHROID CELL; ERYTHROLEUKEMIA; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

ACLARUBICIN; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE, TUMOR; DOXORUBICIN; ERYTHROID CELLS; GATA1 TRANSCRIPTION FACTOR; HEMIN; HEMOGLOBINS; HUMANS; K562 CELLS; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 64049095648     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000212     Document Type: Article

References (52)

1. Knight K, Wade S and Balducci L: Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 116 (Suppl 7A): 11S-26S, 2004.
2. Tas F, Eralp Y, Basaran M, et al: Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol 25: 371-379, 2002.
3. Caro JJ, Salas M, Ward A and Goss G: Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91: 2214-2221, 2001.
4. Andrews NC: Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 113: 1251-1253, 2004.
5. Rizzo JD, Somerfield MR, Hagerty KL, et al: Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/ American Society of Clinical Oncology clinical practice guideline update. Blood 111: 25-41, 2008.
6. Szlosarek P, Charles KA and Balkwill FR: Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 42: 745-750, 2006.
7. Yan L, Anderson GM, DeWitte M and Nakada MT: Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur J Cancer 42: 793-802, 2006.
8. Bokemeyer C, Oechsle K and Hartmann JT: Anaemia in cancer patients: pathophysiology, incidence and treatment. Eur J Clin Invest 35 (Suppl 3): 26-31, 2005.
9. Kurzrock R: The role of cytokines in cancer-related fatigue. Cancer 92 (Suppl 6): 1684-1688, 2001.
10. Allen DA, Breen C, Yaqoob MM and Macdougall IC: Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. J Investig Med 47: 204-211, 1999.
11. Means RT Jr: Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells 13: 32-37, 1995.
12. Papadaki HA, Kritikos HD, Valatas V, Boumpas DT and Eliopoulos GD: Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood 100: 474-482, 2002.
13. Dufour C, Corcione A, Svahn J, et al: TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro. Blood 102: 2053-2059, 2003.
14. + cells. Exp Hematol 30: 1238-1247, 2002.
15. Swiers G, Patient R and Loose M: Genetic regulatory networks programming hematopoietic stem cells and erythroid lineage specification. Dev Biol 294: 525-540, 2006.
16. Pevny L, Simon MC, Robertson E, et al: Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. Nature 349: 257-260, 1991.
17. Morceau F, Schnekenburger M, Dicato M and Diederich M: GATA-1: friends, brothers, and coworkers. Ann NY Acad Sci 1030: 537-554, 2004.
18. Tsai FY and Orkin SH: Transcription factor GATA-2 is required for proliferation/survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation. Blood 89: 3636-3643, 1997.
19. Ferreira R, Ohneda K, Yamamoto M and Philipsen S: GATA1 function, a paradigm for transcription factors in hematopoiesis. Mol Cell Biol 25: 1215-1227, 2005.
20. Hernandez-Hernandez A, Ray P, Litos G, et al: Acetylation and MAPK phosphorylation cooperate to regulate the degradation of active GATA-1. EMBO J 25: 3264-3274, 2006.
21. Lurie LJ, Boyer ME, Grass JA and Bresnick EH: Differential GATA factor stabilities: implications for chromatin occupancy by structurally similar transcription factors. Biochemistry 47: 859-869, 2008.
22. Lu SJ, Rowan S, Bani MR and Ben-David Y: Retroviral integration within the Fli-2 locus results in inactivation of the erythroid transcription factor NF-E2 in Friend erythroleukemias: evidence that NF-E2 is essential for globin expression. Proc Natl Acad Sci USA 91: 8398-8402, 1994.
23. Perkins AC, Peterson KR, Stamatoyannopoulos G, Witkowska HE and Orkin SH: Fetal expression of a human Agamma globin transgene rescues globin chain imbalance but not hemolysis in EKLF null mouse embryos. Blood 95: 1827-1833, 2000.
24. Morceau F, Schnekenburger M, Blasius R, Buck I, Dicato M and Diederich M: Tumor necrosis factor alpha inhibits aclacinomycin A-induced erythroid differentiation of K562 cells via GATA-1. Cancer Lett 240: 203-212, 2006.
25. Ribeil JA, Zermati Y, Vandekerckhove J, et al: Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. Nature 445: 102-105, 2007.
26. Aries A, Trentesaux C, Ottolenghi S, Jardillier JC, Jeannesson P and Doubeikovski A: Activation of erythroid-specific promoters during anthracycline-induced differentiation of K562 cells. Blood 87: 2885-2890, 1996.
27. Morceau F, Aries A, Lahlil R, et al: Evidence for distinct regulation processes in the aclacinomycin - and doxorubicin-mediated differentiation of human erythroleukemic cells. Biochem Pharmacol 51: 839-845, 1996.
28. Schnekenburger M, Morceau F, Duvoix A, et al: Increased glutathione S-transferase P1-1 expression by mRNA stabilization in hemin-induced differentiation of K562 cells. Biochem Pharmacol 68: 1269-1277, 2004.
29. Briegel K, Lim KC, Plank C, Beug H, Engel JD and Zenke M: Ectopic expression of a conditional GATA-2/estrogen receptor chimera arrests erythroid differentiation in a hormone-dependent manner. Genes Dev 7: 1097-1109, 1993.
30. Engert A: Recombinant human erythropoietin in oncology: current status and further developments. Ann Oncol 16: 1584-1595, 2005.
31. Szlosarek PW and Balkwill FR: Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 4: 565-573, 2003.
32. Laftah AH, Sharma N, Brookes MJ, et al: Tumour necrosis factor alpha causes hypoferraemia and reduced intestinal iron absorption in mice. Biochem J 397: 61-67, 2006.
33. Blick M, Sherwin SA, Rosenblum M and Gutterman J: Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 47: 2986-2989, 1987.
34. Dubey S, Shukla P and Nityanand S: Expression of interferon-gamma and tumor necrosis factor-alpha in bone marrow T cells and their levels in bone marrow plasma in patients with aplastic anemia. Ann Hematol 84: 572-577, 2005.
35. Johnson RA, Waddelow TA, Caro J, Oliff A and Roodman GD: Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 74: 130-138, 1989.
36. Wang H, Zhang Y, Cheng Y, et al: Experimental validation of predicted mammalian erythroid cis-regulatory modules. Genome Res 16: 1480-1492, 2006.
37. Tsang AP, Fujiwara Y, Hom DB and Orkin SH: Failure of megakaryopoiesis and arrested erythropoiesis in mice lacking the GATA-1 transcriptional cofactor FOG. Genes Dev 12: 1176-1188, 1998.
38. Crispino JD, Lodish MB, MacKay JP and Orkin SH: Use of altered specificity mutants to probe a specific protein-protein interaction in differentiation: the GATA-1:FOG complex. Mol Cell 3: 219-228, 1999.
39. Boyes J, Byfield P, Nakatani Y and Ogryzko V: Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 396: 594-598, 1998.
40. Hung HL, Lau J, Kim AY, Weiss MJ and Blobel GA: CREB-Binding protein acetylates hematopoietic transcription factor GATA-1 at functionally important sites. Mol Cell Biol 19: 3496-3505, 1999.
41. Lamonica JM, Vakoc CR and Blobel GA: Acetylation of GATA-1 is required for chromatin occupancy. Blood 108: 3736-3738, 2006.
42. Grass JA, Boyer ME, Pal S, Wu J, Weiss MJ and Bresnick EH: GATA-1-dependent transcriptional repression of GATA-2 via disruption of positive autoregulation and domain-wide chromatin remodeling. Proc Natl Acad Sci USA 100: 8811-8816, 2003.
43. La Ferla K, Reimann C, Jelkmann W and Hellwig-Burgel T: Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-kappaB. FASEB J 16: 1811-1813, 2002.
44. Dao MA and Nolta JA: Cytokine and integrin stimulation synergize to promote higher levels of GATA-2, c-myb, and CD34 protein in primary human hematopoietic progenitors from bone marrow. Blood 109: 2373-2379, 2007.
45. Nakano Y, Imagawa S, Matsumoto K, et al: Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxiainducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease. Blood 104: 4300-4307, 2004.
46. Pal S, Cantor AB, Johnson KD, et al: Coregulator-dependent facilitation of chromatin occupancy by GATA-1. Proc Natl Acad Sci USA 101: 980-985, 2004.
47. Cantor AB, Iwasaki H, Arinobu Y, et al: Antagonism of FOG-1 and GATA factors in fate choice for the mast cell lineage. J Exp Med 205: 611-624, 2008.
48. Merika M and Orkin SH: Functional synergy and physical interactions of the erythroid transcription factor GATA-1 with the Kruppel family proteins Sp1 and EKLF. Mol Cell Biol 15: 2437-2447, 1995.
49. Andrews NC, Erdjument-Bromage H, Davidson MB, Tempst P and Orkin SH: Erythroid transcription factor NF-E2 is a haematopoietic-specific basic-leucine zipper protein. Nature 362: 722-728, 1993.
50. Nuez B, Michalovich D, Bygrave A, Ploemacher R and Grosveld F: Defective haematopoiesis in fetal liver resulting from inactivation of the EKLF gene. Nature 375: 316-318, 1995.
51. Perkins AC, Sharpe AH and Orkin SH: Lethal beta-thalassaemia in mice lacking the erythroid CACCC-transcription factor EKLF. Nature 375: 318-322, 1995.
52. Jacobs-Helber SM, Roh KH, Bailey D, et al: Tumor necrosis factor-alpha expressed constitutively in erythroid cells or induced by erythropoietin has negative and stimulatory roles in normal erythropoiesis and erythroleukemia. Blood 101: 524-531, 2003.